Management of Patients with Head and Neck Tumours Presenting at Diagnosis with a Synchronous Second Cancer at Another Anatomic Site

Clinical Oncology

Volumn 23, Issue 3, 2011, Pages 174-181

  Graff, P ^a   Schipman, B ^a,b   Desandes, E ^a   Mecellem, H ^a   Toussaint, B ^c   Cortese, S ^a   Marchal, F ^a   Kaminsky, M C ^a   Geoffrois, L ^a   Peiffert, D ^a  

^a Alexis Vautrin Cancer Center   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Head and neck neoplasms; Multiple primary tumours; Survival analysis; Synchronous neoplasms; Treatment outcome

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; PACLITAXEL;

ADULT; ADVANCED CANCER; ARTICLE; BILE DUCT CARCINOMA; BODY MASS; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; CHRONOTHERAPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CANCER; LARGE CELL CARCINOMA; LARYNX CANCER; LUNG CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MULTIPLE CANCER; OROPHARYNX CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; SECOND CANCER; SQUAMOUS CELL CARCINOMA; THYROID PAPILLARY CARCINOMA; TRACHEA CANCER; TREATMENT DURATION; TUMOR CLASSIFICATION; UROGENITAL TRACT CANCER;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; RADIOTHERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79951944185     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.10.008     Document Type: Article

References (16)

1. Cianfriglia F., Di Gregorio D.A., Manieri A. Multiple primary tumours in patients with oral squamous cell carcinoma. Oral Oncol 1999, 35:157-163.
2. Jones A.S., Morar P., Phillips D.E., Field J.K., Husband D., Helliwell T.R. Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer 1995, 75:1343-1353.
3. Licciardello J.T., Spitz M.R., Hong W.K. Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. Int J Radiat Oncol Biol Phys 1989, 17:467-476.
4. Charlson M., Szatrowski T.P., Peterson J., Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994, 47:1245-1251.
5. Hall W.H., Ramachandran R., Narayan S., Jani A.B., Vijayakumar S. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 2004, 4:94.
6. Singh B., Bhaya M., Stern J., et al. Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study. Laryngoscope 1997, 107:1469-1475.
7. Lo O.S., Law S., Wei W.I., et al. Esophageal cancers with synchronous or antecedent head and neck cancers: a more formidable challenge?. Ann Surg Oncol 2008, 15:1750-1756.
8. Krabbe C.A., Pruim J., van der Laan B.F., Rodiger L.A., Roodenburg J.L. FDG-PET and detection of distant metastases and simultaneous tumors in head and neck squamous cell carcinoma: a comparison with chest radiography and chest CT. Oral Oncol 2009, 45:234-240.
9. Senft A., de Bree R., Hoekstra O.S., et al. Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: a prospective multicenter trial. Radiother Oncol 2008, 87:221-229.
10. Salahudeen H.M., Balan A., Naik K., Mirsadraee S., Scarsbrook A.F. Impact of the introduction of integrated PET-CT into the preoperative staging pathway of patients with potentially operable oesophageal carcinoma. Clin Radiol 2008, 63:765-773.
11. Kato H., Miyazaki T., Nakajima M., et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 2005, 103:148-156.
12. Erasmus J.J., Rohren E., Swisher S.G. Prognosis and reevaluation of lung cancer by positron emission tomography imaging. Proc Am Thorac Soc 2009, 6:171-179.
13. Ung Y.C., Maziak D.E., Vanderveen J.A., et al. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst 2007, 99:1753-1767.
14. Murakami R., Uozumi H., Hirai T., et al. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2007, 68:377-382.
15. Grills I.S., Yan D., Black Q.C., Wong C.Y., Martinez A.A., Kestin L.L. Clinical implications of defining the gross tumor volume with combination of CT and 18FDG-positron emission tomography in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007, 67:709-719.
16. Haerle S.K., Strobel K., Hany T.F., Sidler D., Stoeckli S.J. (18)F-FDG-PET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma. Head Neck 2010, 32:319-325.